{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-033991","form_type":"8-K","ticker":"VYNE","cik":"0001566044","company_name":"VYNE Therapeutics Inc.","filed_at":"2022-03-15T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.034168+00:00","generated_at":"2026-06-26T22:45:50.435340+00:00","sec_items":["1.01","5.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"VYNE Therapeutics enters $30M equity line with Lincoln Park Capital; names Tyler Zeronda CFO","bullets":["Up to $30M of common stock can be sold to Lincoln Park over 36 months; 1,667,593 commitment shares issued.","Regular purchases up to 200,000 shares/day (increased to 400,000 if closing price >= $1.00); pricing at discount to market.","Exchange cap of 11,227,637 shares (19.99% of outstanding) unless stockholder approval or avg price >= $0.545.","Tyler Zeronda appointed CFO and Treasurer effective March 14, 2022; annual base salary $340,000 with 40% target bonus.","Proceeds from equity line expected to be used for working capital and general corporate purposes."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-033991","json":"https://secwatch.observer/filing/0001104659-22-033991.json","markdown":"https://secwatch.observer/filing/0001104659-22-033991.md","text":"https://secwatch.observer/filing/0001104659-22-033991.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1566044/000110465922033991/0001104659-22-033991-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1566044/000110465922033991/tm229153d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T22:45:50.435340+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"69c1f76f8a","claim":"Tyler Zeronda was named as Chief Financial Officer and Treasurer at VYNE Therapeutics Inc..","evidence_excerpt":"On March 14, 2022, the Company named Tyler Zeronda as the Chief Financial Officer and Treasurer of the Company effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1566044/000110465922033991/0001104659-22-033991-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"named"},{"label":"Role","value":"Chief Financial Officer and Treasurer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}